General Information of Drug (ID: DMBF3ZE)

Drug Name
PMID30273516-Compound-39 Drug Info
Cross-matching ID
TTD Drug ID
DMBF3ZE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Glutaminase (GLS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CB-839 DM094UH Breast cancer 2C60-2C65 Phase 2 [2]
PMID30273516-Compound-13 DMK9TJP N. A. N. A. Patented [1]
PMID30273516-Compound-22a DMVZA0U N. A. N. A. Patented [1]
PMID30273516-Compound-37 DM8NBJV N. A. N. A. Patented [1]
PMID30273516-Compound-12 DMIWEZH N. A. N. A. Patented [1]
PMID30273516-Compound-38 DMRPJBF N. A. N. A. Patented [1]
PMID30273516-Compound-22b DMZ5O3K N. A. N. A. Patented [1]
PMID30273516-Compound-1 DM52MKV N. A. N. A. Patented [1]
PMID30273516-Compound-15 DMSD647 N. A. N. A. Patented [1]
PMID30273516-Compound-41 DM5UBMJ N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutaminase (GLS) TTCW0KX GLSK_HUMAN; GLSL_HUMAN Inhibitor [1]

References

1 Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
2 Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901.